BR112015030490A2 - (+)-5-(3,4-difluorofenil)-5-[(3-metil-2-oxopiridin-1(2h)-il)metil]-imidazolidino-2,4-diona e medicamento contendo a mesma - Google Patents

(+)-5-(3,4-difluorofenil)-5-[(3-metil-2-oxopiridin-1(2h)-il)metil]-imidazolidino-2,4-diona e medicamento contendo a mesma

Info

Publication number
BR112015030490A2
BR112015030490A2 BR112015030490A BR112015030490A BR112015030490A2 BR 112015030490 A2 BR112015030490 A2 BR 112015030490A2 BR 112015030490 A BR112015030490 A BR 112015030490A BR 112015030490 A BR112015030490 A BR 112015030490A BR 112015030490 A2 BR112015030490 A2 BR 112015030490A2
Authority
BR
Brazil
Prior art keywords
methyl
imidazolidine
dione
oxopyridin
difluorophenyl
Prior art date
Application number
BR112015030490A
Other languages
English (en)
Other versions
BR112015030490B1 (pt
Inventor
Kamimura Daigo
Kamei Noriyuki
Tokuoka Shota
Sumikawa Yoshitake
Original Assignee
Kaken Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaken Pharma Co Ltd filed Critical Kaken Pharma Co Ltd
Publication of BR112015030490A2 publication Critical patent/BR112015030490A2/pt
Publication of BR112015030490B1 publication Critical patent/BR112015030490B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quick-Acting Or Multi-Walled Pipe Joints (AREA)
  • Medicinal Preparation (AREA)

Abstract

1/1 resumo “(+)-5-(3,4-difluorofenil)-5-[(3-metil-2-oxopiridin-1(2h)-il)metil] imidazolidino-2,4-diona e medicamento contendo a mesma” a presente invenção refere-se a (+)-5-(3,4-difluorofenil)-5-[(3-metil-2oxopiridin- 1(2h)-il)metil]imidazolidino-2,4-diona ou um sal da mesma. também é fornecido um medicamento contendo como o ingrediente ativo a (+)-5-(3,4difluorofenil)- 5-[(3-metil-2-oxopiridin-1(2h)-il)metil]imidazolidino-2,4-diona ou um sal da mesma.
BR112015030490-7A 2013-06-07 2014-06-06 (+)-5-(3,4-difluorofenil)-5-[(3-metil-2-oxopiridin-1(2h)-il)metil]-imidazolidino-2,4-diona e medicamento contendo a mesma BR112015030490B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013-120692 2013-06-07
JP2013120692 2013-06-07
PCT/JP2014/065060 WO2014196623A1 (ja) 2013-06-07 2014-06-06 （＋）－５－（３，４－ジフルオロフェニル）－５－［（３－メチル－２－オキソピリジン－１（２ｈ）－イル）メチル］イミダゾリジン－２，４－ジオンおよびそれを含有する医薬

Publications (2)

Publication Number Publication Date
BR112015030490A2 true BR112015030490A2 (pt) 2017-07-25
BR112015030490B1 BR112015030490B1 (pt) 2022-01-18

Family

ID=52008252

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015030490-7A BR112015030490B1 (pt) 2013-06-07 2014-06-06 (+)-5-(3,4-difluorofenil)-5-[(3-metil-2-oxopiridin-1(2h)-il)metil]-imidazolidino-2,4-diona e medicamento contendo a mesma

Country Status (19)

Country Link
US (1) US9518041B2 (pt)
EP (1) EP3006437B1 (pt)
JP (1) JP6247689B2 (pt)
KR (2) KR102321814B1 (pt)
CN (1) CN105531270B (pt)
AU (1) AU2014275835B2 (pt)
BR (1) BR112015030490B1 (pt)
CA (1) CA2913858C (pt)
ES (1) ES2818931T3 (pt)
HK (1) HK1221219A1 (pt)
IL (1) IL242861B (pt)
MX (1) MX364780B (pt)
MY (1) MY173075A (pt)
NZ (1) NZ714700A (pt)
PH (1) PH12015502661A1 (pt)
RU (1) RU2668072C2 (pt)
SG (1) SG11201509835RA (pt)
TW (1) TWI636782B (pt)
WO (1) WO2014196623A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2014196624A1 (ja) * 2013-06-07 2017-02-23 科研製薬株式会社 血小板の機能を維持するための組成物
CN107304205B (zh) * 2016-04-22 2020-10-30 上海医药工业研究院 一种马拉韦罗中间体及其制备方法
ES2865854T3 (es) * 2016-09-23 2021-10-18 Kaken Pharma Co Ltd Método para producir (r)-5-(3,4-difluorofenil)-5-[(3-metil-2-oxopiridin-1(2h)-il)metil]imidazolidin-2,4-diona y un producto intermedio para producir la misma

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002074750A1 (en) * 2001-03-15 2002-09-26 Astrazeneca Ab Metalloproteinase inhibitors
EP1431285B1 (en) 2001-09-07 2009-01-07 Kaken Pharmaceutical Co., Ltd. Reverse hydroxamic acid derivatives
GB0221246D0 (en) 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
WO2004033632A2 (en) 2002-10-04 2004-04-22 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)
US7132432B2 (en) 2003-06-05 2006-11-07 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)
GB0405101D0 (en) * 2004-03-06 2004-04-07 Astrazeneca Ab Compounds
WO2006019768A1 (en) 2004-07-16 2006-02-23 Schering Corporation Hydantoin derivatives for the treatment of inflammatory disorders
US7488745B2 (en) 2004-07-16 2009-02-10 Schering Corporation Compounds for the treatment of inflammatory disorders
US7504424B2 (en) 2004-07-16 2009-03-17 Schering Corporation Compounds for the treatment of inflammatory disorders
AR059037A1 (es) 2006-01-17 2008-03-12 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
EP2301922A4 (en) * 2008-06-17 2012-06-06 Astellas Pharma Inc pyridone
US8450355B2 (en) 2008-09-24 2013-05-28 Merck Sharp & Dohme Corp. Compounds for the treatment of inflammatory diseases
WO2010054278A2 (en) 2008-11-10 2010-05-14 Schering Corporation Compounds for the treatment of inflammatory disorders
US9447072B2 (en) 2011-12-09 2016-09-20 Kaken Pharmaceutical Co., Ltd. Pyridone derivative and pharmaceutical containing same

Also Published As

Publication number Publication date
TW201536285A (zh) 2015-10-01
CA2913858C (en) 2021-07-20
PH12015502661B1 (en) 2016-03-07
CN105531270B (zh) 2017-09-05
MY173075A (en) 2019-12-24
HK1221219A1 (zh) 2017-05-26
EP3006437A4 (en) 2017-03-15
NZ714700A (en) 2020-09-25
MX364780B (es) 2019-05-07
TWI636782B (zh) 2018-10-01
SG11201509835RA (en) 2015-12-30
KR20160016834A (ko) 2016-02-15
RU2668072C2 (ru) 2018-09-27
CN105531270A (zh) 2016-04-27
JP6247689B2 (ja) 2017-12-13
WO2014196623A1 (ja) 2014-12-11
BR112015030490B1 (pt) 2022-01-18
KR102379801B1 (ko) 2022-03-28
EP3006437A1 (en) 2016-04-13
US20160130248A1 (en) 2016-05-12
PH12015502661A1 (en) 2016-03-07
JPWO2014196623A1 (ja) 2017-02-23
US9518041B2 (en) 2016-12-13
KR102321814B1 (ko) 2021-11-05
AU2014275835B2 (en) 2018-08-16
AU2014275835A1 (en) 2015-12-24
IL242861B (en) 2018-08-30
KR20210133326A (ko) 2021-11-05
EP3006437B1 (en) 2020-08-05
ES2818931T3 (es) 2021-04-14
RU2015156531A (ru) 2017-07-14
MX2015016828A (es) 2016-04-11
CA2913858A1 (en) 2014-12-11

Similar Documents

Publication Publication Date Title
NZ745556A (en) Androgen receptor modulator and uses thereof
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
DK201470535A (en) Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
PH12016500356A1 (en) Nsaid and sigma receptor ligand combinations
BR112013008005A2 (pt) composição farmacêutica kpiquida pronta para uso para adminidtração parental a um indivíduo
TR201904614T4 (tr) Novel pyrazole derivative.
BR112015016930A2 (pt) formulações farmacêuticas estabilizadas de análogos de insulina e/ou derivados de insulina
TN2015000440A1 (en) Alpha-2 adrenoceptor and sigma receptor ligand combinations
PH12016501095A1 (en) Gabapentinoids and sigma receptor ligands combinations
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
BR112015008459A2 (pt) método veterinário de aliviar a aversão ao ruído
BR112015026967A8 (pt) fenoxietil di-hidro-1h-isoquinolina, seus usos, e composição farmacêutica
BR112017009521A2 (pt) comprimido de múltiplas camadas que contém um fármaco instável à luz
BR112015030490A2 (pt) (+)-5-(3,4-difluorofenil)-5-[(3-metil-2-oxopiridin-1(2h)-il)metil]-imidazolidino-2,4-diona e medicamento contendo a mesma
BR112012028047A2 (pt) sistema de cateter, cateter, método de administração de um agente a um paciente e método para variar uma dosagem de um agente ativo
BR112019018028A2 (pt) Composto, combinação, e. uso de um composto ou um sal farmaceuticamente aceitável do mesmo
BR112015010823A2 (pt) composto de 2-piridona
UA109944U (uk) Фармацевтична композиція для зниження рівня n-оксиду триметиламіну
BR112016008704A8 (pt) derivados de indol-urea glucopiranosil-substituídos, composições farmacêuticas, e seus usos
EA201690762A1 (ru) {4-[5-(3-хлорфенокси)оксазоло[5,4-d]пиримидин-2-ил]-2,6-диметилфенокси}уксусная кислота для применения при предупреждении или лечении острого повреждения почек
BR112015022000A2 (pt) drogas de combinações farmacêuticas
GR20140200047U (el) Φαρμακευτικη αντλια εγχυσης αμεσης εισαγωγης
PL401992A1 (pl) 2-benzoiloamino-5-(izochinolin-3-ylo)-1,3,4-tiadiazol, sposób jego wytwarzania oraz zastosowanie medyczne
PL414785A1 (pl) Kwas 3-dodecylosulfanylomasłowy do zastosowania jako lek, zwłaszcza do zapobiegania rozwojowi insulinooporności oraz kompozycja farmaceutyczna zawierająca kwas 3-dodecylosulfanylomasłowy jako substancję czynną
MD20150017A2 (ro) Utilizarea preparatului Polibiolin la pacienţii cu ciroză hepatică

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/06/2014, OBSERVADAS AS CONDICOES LEGAIS.